甲状腺激素抵抗α型的转录抑制遗传与药理靶向研究
本研究利用Thra1PV/+小鼠(RTHα模型)及Ncor1ΔID/ΔID小鼠,探讨TRα/NCoR1/HDAC阻遏复合物在RTHα骨骼表现中的作用,并测试HDAC抑制剂SAHA的疗效。结果显示SAHA对野生型或突变小鼠的骨骼结构、矿化或强度均无有益或有害影响,提示SAHA不太可能改善RTHα的骨骼表现。
要点
- SAHA抑制HDAC对RTHα模型小鼠骨骼无改善作用。
- NCoR1在调控成年骨量和骨强度中具有新作用。
- TRα1对骨骼发育和成年骨量调节至关重要。
核心结论
- SAHA治疗不太可能改善RTHα的骨骼表现。
- TRα1在骨骼发育和成年骨量调节中起关键作用。
- NCoR1在调控成年骨量和骨强度中具有新作用。
研究设计与样本
- 研究分析了Thra1PV/+小鼠、Ncor1ΔID/ΔID小鼠及Thra1PV/+Ncor1ΔID/ΔID双突变成年小鼠的骨骼表型。
- 野生型、Thra1PV/+、Ncor1ΔID/ΔID和双突变小鼠接受SAHA治疗以评估HDAC抑制效果。
主要发现
- Thra1PV/+小鼠表现出严重骨骼发育不良,特征为身材矮小、骨形态异常和骨矿物质含量增加。
- Ncor1ΔID/ΔID小鼠骨长度正常,但皮质骨量、矿化和强度增加。
- 双突变小鼠与Thra1PV/+小鼠相比骨骼异常仅小幅改善。
- SAHA治疗对野生型或突变小鼠的骨骼结构、矿化或强度无有益或有害影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid hormones act in bone and cartilage via thyroid hormone receptor alpha (TRα). In the absence of triiodothyronine (T3), TRα interacts with co-repressors, including nuclear receptor co-repressor-1 (NCoR1), which recruit histone deacetylases (HDACs) and mediate transcriptional repression. Dominant-negative mutations of TRα cause resistance to thyroid hormone alpha (RTHα; OMIM 614450), characterized by excessive repression of T3 target genes leading to delayed skeletal development, growth retardation, and bone dysplasia. Treatment with thyroxine has been of limited benefit, even in mildly affected individuals, and there is a need for new therapeutic strategies. It was hypothesized that (i) the skeletal manifestations of RTHα are mediated by the persistent TRα/NCoR1/HDAC repressor complex containing mutant TRα, and (ii) treatment with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) would ameliorate these manifestations. Methods: The skeletal phenotypes of (i) Thra1PV/+ mice, a well characterized model of RTHα; (ii) Ncor1ΔID/ΔID mice, which express an NCoR1 mutant that fails to interact with TRα; and (iii) Thra1PV/+Ncor1ΔID/ΔID double-mutant adult mice were determined. Wild-type, Thra1PV/+, Ncor1ΔID/ΔID, and Thra1PV/+Ncor1ΔID/ΔID double-mutant mice were also treated with SAHA to determine whether HDAC inhibition results in amelioration of skeletal abnormalities. Results:Thra1PV/+ mice had a severe skeletal dysplasia, characterized by short stature, abnormal bone morphology, and increased bone mineral content. Despite normal bone length, Ncor1ΔID/ΔID mice displayed increased cortical bone mass, mineralization, and strength. Thra1PV/+Ncor1ΔID/ΔID double-mutant mice displayed only a small improvement of skeletal abnormalities compared to Thra1PV/+ mice. Treatment with SAHA to inhibit histone deacetylation had no beneficial or detrimental effects on bone structure, mineralization, or strength in wild-type or mutant mice. Conclusions: These studies indicate treatment with SAHA is unlikely to improve the skeletal manifestations of RTHα. Nevertheless, the findings (i) confirm that TRα1 has a critical role in the regulation of skeletal development and adult bone mass, (ii) suggest a physiological role for alternative co-repressors that interact with TR in skeletal cells, and (iii) demonstrate a novel role for NCoR1 in the regulation of adult bone mass and strength.
引用
- Freudenthal B, Shetty S, Butterfield NC, et al. Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha. Thyroid. 2019. PMID: 30760120. doi:10.1089/thy.2018.0399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。